+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Polpharma SA - Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 29 Pages
  • April 2026
  • GlobalData
  • ID: 4058164
Polpharma SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Report Scope

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - The analyst’s summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Polpharma SA (Polpharma), a subsidiary of Polpharma Group BV, is a pharmaceutical company engaged in the research, development, manufacturing, and distribution of a wide range of medical drugs. The company's main activities include the production of prescription drugs, over-the-counter medications, hospital drugs, dietary supplements, cosmetic products, active ingredients, and medical devices. Polpharma's product portfolio covers therapeutic areas such as cardiology, gastroenterology, neurology, pulmonary, anti-infectives, dermatology, and ophthalmology. The company offers its products to healthcare providers, hospitals, and pharmacies in Central and Eastern Europe, the Caucasus, and Central Asia. It operates production plants in Poland. Polpharma is headquartered in Starogard Gdanski, Pomeranian Voivodeship, Poland.

Polpharma SA Key Recent Developments

  • Mar 13, 2026: Polpharma Opens Office in India to Strengthen Global Collaboration and API Supply Chain Resilience
  • Feb 12, 2026: Polpharma SA Launches Project Under STEP Initiative
  • Aug 06, 2025: Fresenius Kabi signs global licensing deal for Polpharma’s vedolizumab biosimilar

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with the analyst’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Polpharma SA - Key Facts
  • Polpharma SA - Key Employees
  • Polpharma SA - Key Employee Biographies
  • Polpharma SA - Major Products and Services
  • Polpharma SA - History
  • Polpharma SA - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Polpharma SA - Business Description
  • R&D Overview
  • Polpharma SA - Corporate Strategy
  • Polpharma SA - SWOT Analysis
  • SWOT Analysis - Overview
  • Polpharma SA - Strengths
  • Polpharma SA - Weaknesses
  • Polpharma SA - Opportunities
  • Polpharma SA - Threats
  • Polpharma SA - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Polpharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Polpharma SA, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Polpharma SA, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • Mar 13, 2026: Polpharma Opens Office in India to Strengthen Global Collaboration and API Supply Chain Resilience
  • Feb 12, 2026: Polpharma SA Launches Project Under STEP Initiative
  • Aug 06, 2025: Fresenius Kabi signs global licensing deal for Polpharma’s vedolizumab biosimilar
Section 5 - Appendix
  • Methodology
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Polpharma SA, Key Facts
  • Polpharma SA, Key Employees
  • Polpharma SA, Key Employee Biographies
  • Polpharma SA, Major Products and Services
  • Polpharma SA, History
  • Polpharma SA, Other Locations
  • Polpharma SA, Subsidiaries
  • Polpharma SA, Key Competitors
  • Polpharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Polpharma SA, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Polpharma SA, Recent Deals Summary
List of Figures
  • Polpharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Polpharma SA, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026